Taking ‘baby aspirin' doses daily cuts the heightened risk of bowel cancer in half in those with Lynch Syndrome, a genetic ...

With all the painkillers out there, we sometimes forget one that has been around forever: aspirin! It has been called the ...

Patients with antiphospholipid antibodies (aPL) are at increased risk for arterial or venous thrombosis. There is, however, significant heterogeneity among patients according to clinical and ...

Objective A comparison of cryoneurolysis or radio frequency (RF) with placebo in patients with facetogenic chronic low back pain (LBP) for patient global impression of change (PGIC), pain intensity, ...

Bayer submits New Drug Application (NDA) for gadoquatrane: The investigational macrocyclic gadolinium-based contrast agent is designed for contrast-enhanced MRI of the central nervous system and other ...

MINNEAPOLIS — Universal presumption of low-dose aspirin, instead of risk-based screenings, can increase uptake for preeclampsia prevention in underserved populations, according to a speaker at ...

Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs By Solve M.E. Jun 17, 2025 Updated Jun 17, 2025 ...

The daily use of low-dose aspirin against heart disease may have taken another knock. New research shows that the practice may not provide the added benefit of reduced heart attack risk to Black ...

A NEWBORN baby girl passed away shortly after being given a drug overdose by hospital staff. Polly Ida Lindop was barely a day old when she died at St Mary’s Hospital in Manchester on March 1… ...

Effect of Helicobacter Pylori Infection and Low-Dose Aspirin Use on Iron Stores in the Elderly Arthur Kaffes, John Cullen, Hazel Mitchell, Peter H Katelaris Disclosures ...

High-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course ...

This is a single-arm, Simon 2-stage trial. Patients with synovial sarcomas who had progressed on at least two lines were administered daily regorafenib (80/120 mg alternating once daily per orally).